About Regulus Therapeutics Inc. (adapted from Regulus Therapeutics Inc. prospectus): Regulus is a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus uses their microRNA product platform to develop chemically modified, single-stranded oligonucleotides that they call anti-miRs. They use these anti-miRs to modulate microRNAs and by doing so return diseased cells to their healthy state.
This description is adapted from Regulus Therapeutics Inc. prospectus. This description is not intended to be a recommendation to buy stock from this company. We do not claim that all of the statements above were researched and found to be true. We present them as a general description based on what the company has said about itself at the time that they submitted their prospectus for an IPO offering. To see the company's full description, view their prospectus..
IPO Boutique aggregates information on public companies and private companies, such as Regulus Therapeutics Inc. IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Our research is available by annual or monthly subscription or by one-week snapshots and single-company reports. Be informed.
Get our comprehensive reports. Monthly or Annual subscriptions—